Clinical importance of micro albuminuria in diabetes and hypertension

被引:38
作者
Bakris, GL [1 ]
机构
[1] Rush Univ, Med Ctr, Hypertens Ctr, Chicago, IL 60612 USA
关键词
D O I
10.1007/s11906-004-0053-1
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Numerous studies document an almost linear association between the level of albuminuria and risk for a cardiovascular event. Recent data also demonstrate a strong association between the presence of microalbuminuria and elevations in C-reactive protein. Therefore, the increased membrane permeability that generates microalbuminuria might be secondary to an inflammatory process. Progression from microalbuminuria to macroalbuminuria indicates worsening of vascular disease and presence of kidney disease. Recent pharmacologic interventions have resulted in significant delay and even arrest of progression of microalbuminuria to macroalbuminuria as well as kidney disease progression. Therefore, focus should be placed on use of anti hypertensive agents that not only lower blood pressure but also lower or normalize albuminuria levels. All recent guideline statements support the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Further lowering of albuminuria may be achieved by adding verapamil, diltiazem, or an ARB to an ACE inhibitor.
引用
收藏
页码:352 / 356
页数:5
相关论文
共 37 条
[1]  
ABOSAIF NY, 2004, AM J KIDNEY DIS, V43, P1
[2]   Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) [J].
Adler, AI ;
Stevens, RJ ;
Manley, SE ;
Bilous, RW ;
Cull, CA ;
Holman, RR .
KIDNEY INTERNATIONAL, 2003, 63 (01) :225-232
[3]   Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study [J].
Adler, AI ;
Stratton, IM ;
Neil, HAW ;
Yudkin, JS ;
Matthews, DR ;
Cull, CA ;
Wright, AD ;
Turner, RC ;
Holman, RR .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258) :412-419
[4]   Differential effects of calcium antagonist subclasses on markers of nephropathy progression [J].
Bakris, GL ;
Weir, MR ;
Secic, M ;
Campbell, B ;
Weis-McNulty, A .
KIDNEY INTERNATIONAL, 2004, 65 (06) :1991-2002
[5]   Effects of blood pressure level on progression of diabetic nephropathy - Results from the RENAAL study [J].
Bakris, GL ;
Weir, MR ;
Shanifar, S ;
Zhang, ZX ;
Douglas, J ;
van Dijk, DJ ;
Brenner, BM .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (13) :1555-1565
[6]   Salt intake and reductions in arterial pressure and proteinuria - Is there a direct link? [J].
Bakris, GL ;
Weir, MR .
AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (12) :S200-S206
[7]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[8]  
Clausen P, 2001, CIRCULATION, V103, P1869
[9]   Role of nephrin in renal disease including diabetic nephropathy [J].
Cooper, ME ;
Mundel, P ;
Boner, G .
SEMINARS IN NEPHROLOGY, 2002, 22 (05) :393-398
[10]   Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke [J].
Di Napoli, M ;
Papa, F .
STROKE, 2003, 34 (12) :2922-2929